Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
Case Comprehensive Cancer Center
Study ID
NCT00055640
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
    Rituximab IV over 3-6 hours.Treatment repeats every 21 days for 3-8 courses.
  • cyclophosphamide — DRUG
    Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.
  • doxorubicin hydrochloride — DRUG
    Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.
  • prednisone — DRUG
    Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.
  • vincristine sulfate — DRUG
    Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.
  • microarray analysis — GENETIC
    genetic testing

Study Details

RATIONALE: Analyzing genes that are present in cancer cells may be useful as a method for predicting the response of non-Hodgkin's lymphoma to cancer treatment. Imaging procedures such as positron emission tomography (PET) scans may improve the ability to measure how well cancer has responded to treatment. PURPOSE: This phase II trial is studying molecular risk assessment to see how well it works in predicting response to therapy in patients who are receiving treatment for non-Hodgkin's lymphoma.

Key Dates

Start date
Oct 31, 2002
Status verified
Jun 2010
Primary completion
Apr 30, 2005
Completion
Mar 31, 2006

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Molecular risk assessment to see how well it works in predicting response to therapy in patients who are receiving treatment for non-Hodgkin's lymphoma. [ Time Frame: Results from the genetic testing and PET scans at baseline and after course 3 to determine response. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer CenterClevelandOhio44106-7284-

Find similar trials in Cleveland, OH

By research site
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center· Cleveland, OH

Related Studies